The ASGR1 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population designed to disrupt the ASGR1 gene in the HT29 human colorectal adenocarcinoma cell line. This gene-edited model provides a heterogeneous pool of knockout cells, enabling loss-of-function analysis without clonal selection and preserving the parental line??s genetic diversity while eliminating ASGR1 expression in a substantial fraction of the population. Such a format allows robust comparison of ASGR1-dependent and -independent phenotypes within the same cellular background, facilitating functional studies in cancer biology.
The HT29 host cell line was originally derived from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female and displays adherent epithelial morphology. It is a widely accepted intestinal epithelial model extensively employed in colorectal cancer research, including investigations of drug response, signal transduction, and oncogenic mechanisms. HT29 cells provide a well-characterized, genetically tractable system suitable for dissecting the roles of genes not classically linked to colon tissue, such as the hepatic receptor ASGR1.
ASGR1 encodes the major subunit of the asialoglycoprotein receptor, a hepatic C-type lectin that clears desialylated glycoproteins via clathrin-mediated endocytosis. The receptor forms a complex with ASGR2 and the AP2 adaptor, internalizing ligands for delivery through early endosomes to lysosomes. Beyond its canonical role in glycoprotein homeostasis, ASGR1 influences NF-??B signaling, with evidence that it modulates downstream targets like IL-8 and TNF??. Upstream regulators include HNF4??, glucocorticoids, and IL-6, while pathway components such as dynamin, I??B??, and NF-??B p65 further connect ASGR1 to inflammatory and apoptotic responses.
Knocking out ASGR1 in HT29 cells provides a valuable model for investigating its extrahepatic functions in colorectal cancer. Although predominantly studied in hepatic contexts, ASGR1 expression in colon cancer cells may impact glycoprotein turnover and immune signaling pathways, potentially affecting tumor progression via NF-??B and JAK-STAT cascades. This polyclonal knockout population enables dissection of how ASGR1 loss alters cellular responses to desialylated ligands and modulates apoptotic thresholds, offering insights into its contribution to oncogenic processes and immune modulation.
Research applications with these polyclonal knockout cells include the study of ASGR1-mediated endocytosis, glycoprotein trafficking, and NF-??B pathway activation in colorectal cancer. Users can employ techniques such as Western blotting and RT-qPCR to assess pathway components, flow cytometry to quantify receptor surface expression, and desialylated ligand uptake assays to monitor endocytic function. Additional applications encompass drug delivery targeting ASGR1, phospho-signaling analysis of NF-??B p65 and I??B??, and cell viability/apoptosis assays to evaluate ASGR1’s impact on cancer cell fate. For further information, please contact Ascent Research.
